OncoMatch/Breast Cancer/HER2 (ERBB2)
Breast CancerHER2 (ERBB2) Clinical Trials
HER2 overexpression or amplification defines HER2-positive breast cancer — approximately 20% of cases — and predicts response to targeted therapy. Trastuzumab, pertuzumab, ado-trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), and neratinib (adjuvant) are approved across disease stages. Trials span neoadjuvant to metastatic settings and include HER2-low disease (IHC 1+ or 2+/FISH-negative), a recently validated therapeutic category.
Top recruiting HER2 (ERBB2) Breast Cancer trials
Ranked by phase and US site count.
See all trials matched to your profile →S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
SWOG Cancer Research Network
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
BriaCell Therapeutics Corporation
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Greenwich LifeSciences, Inc.
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
AstraZeneca
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Daiichi Sankyo
More HER2 (ERBB2) Breast Cancer trials
See all in search →19 international trials (no US sites)
FDA-approved therapies for HER2 (ERBB2) Breast Cancer
Approved agents for this molecular target. Indication labels specify the approved patient population — some approvals apply to specific variants only.